top of page

Antisense Therapeutics - Research Report

  • Writer: DGWA
    DGWA
  • Feb 1, 2021
  • 1 min read

Corporate Connect has published a research report on Antisense Therapeutics:



Sarepta Therapeutics’ (NASDAQ: SRPT) SRP-9001, a putative gene therapy (GT) for all Duchenne muscular dystrophy (DMD) patients has failed to demonstrate an improvement clinical function in a double- blind, randomised, placebo-controlled phase II trial in 41 patients. This event significantly improves the commercial prospects Antisense Therapeutics’ DMD therapy, ATL1102.



Post: Blog2_Post
bottom of page